Multivariate GWAS of Alzheimer’s disease CSF biomarker profiles implies GRIN2D in synaptic functioning

Alexander Neumann, Olena Ohlei, Fahri Küçükali, Isabelle J. Bos, Jigyasha Timsina, Stephanie Vos, Dmitry Prokopenko, Betty M. Tijms, Ulf Andreasson, Kaj Blennow, Rik Vandenberghe, Philip Scheltens, Charlotte E. Teunissen, Sebastiaan Engelborghs, Giovanni B. Frisoni, Oliver Blin, Jill C. Richardson, Régis Bordet, Alberto Lleó, Daniel AlcoleaJulius Popp, Thomas W. Marsh, Priyanka Gorijala, Christopher Clark, Gwendoline Peyratout, Pablo Martinez-Lage, Mikel Tainta, Richard J.B. Dobson, Cristina Legido-Quigley, Christine Van Broeckhoven, Rudolph E. Tanzi, Mara ten Kate, Christina M. Lill, Frederik Barkhof, Carlos Cruchaga, Simon Lovestone, Johannes Streffer, Henrik Zetterberg, Pieter Jelle Visser, Kristel Sleegers, Lars Bertram*

*Corresponding author for this work
17 Citations (Scopus)

Abstract

Background: Genome-wide association studies (GWAS) of Alzheimer’s disease (AD) have identified several risk loci, but many remain unknown. Cerebrospinal fluid (CSF) biomarkers may aid in gene discovery and we previously demonstrated that six CSF biomarkers (β-amyloid, total/phosphorylated tau, NfL, YKL-40, and neurogranin) cluster into five principal components (PC), each representing statistically independent biological processes. Here, we aimed to (1) identify common genetic variants associated with these CSF profiles, (2) assess the role of associated variants in AD pathophysiology, and (3) explore potential sex differences. Methods: We performed GWAS for each of the five biomarker PCs in two multi-center studies (EMIF-AD and ADNI). In total, 973 participants (n = 205 controls, n = 546 mild cognitive impairment, n = 222 AD) were analyzed for 7,433,949 common SNPs and 19,511 protein-coding genes. Structural equation models tested whether biomarker PCs mediate genetic risk effects on AD, and stratified and interaction models probed for sex-specific effects. Results: Five loci showed genome-wide significant association with CSF profiles, two were novel (rs145791381 [inflammation] and GRIN2D [synaptic functioning]) and three were previously described (APOE, TMEM106B, and CHI3L1). Follow-up analyses of the two novel signals in independent datasets only supported the GRIN2D locus, which contains several functionally interesting candidate genes. Mediation tests indicated that variants in APOE are associated with AD status via processes related to amyloid and tau pathology, while markers in TMEM106B and CHI3L1 are associated with AD only via neuronal injury/inflammation. Additionally, seven loci showed sex-specific associations with AD biomarkers. Conclusions: These results suggest that pathway and sex-specific analyses can improve our understanding of AD genetics and may contribute to precision medicine.

Original languageEnglish
Article number79
JournalGenome Medicine
Volume15
Issue number1
DOIs
Publication statusPublished - 12.2023

Funding

FundersFunder number
Departments of Neurology and Psychiatry at Washington University School of Medicine
Mayo Clinic Brain Bank
EU IMI
Familjen Erling-Perssons Stiftelse
Rush University
CurePSP
Hope Center for Neurological Disorders
EPAD
Anonymous foundation
New York Stem Cell Foundation
National Center for Geriatrics and Gerontology
European Union’s HorizonEurope Research and Innovation Programme
Chan Zuckerberg Initiative
National Institute of Biomedical Imaging and Bioengineering
Arizona Biomedical Research Commission
National Institute for Health and Care Research
Fonds Wetenschappelijk Onderzoek
Janssen Medical Ltd
Lifebrain EU Horizon 2020
UCLH Biomedical Research Centre
Department of Health of the Basque Government
Akrivia Health Ltd
University of Florida
Icahn School of Medicine at Mount Sinai
Olav Thon Stiftelsen
Mayo and Michael J Fox foundations
Koichi Iijima
Columbia University
Cure Alzheimer's Fund
Alzheimer's Disease Neuroimaging Initiative
Universiteit Antwerpen
European Research Council
DOD ADNI
Michael J. Fox Foundation for Parkinson's Research
Arizona Department of Health Services
AD Strategic Fund
National Institute on Aging
AstraZeneca GmbH
Neurogenomics and Informatics Center
Horizon 2020 Framework Programme666992, 732592
National Institutes of HealthU01AG006786, U01AG058922, P30AG19610, RF1AG058501, U01AG61356, R01AG044546, U24AG061340, P30AG10161, R01 AG032990, U24NS072026, U01AG046139, R01NS080820, R01AG025711, R01AG036836, P30AG72975, R01AG017216, U01AG006576, RF1AG057440, U01AG046170, R01AG018023, RF1AG053303, R01AG003949, P50 AG016574, U01AG46152, P01AG003991, U01 AG024904, R01AG17917, R01AG15819
H2020 Marie Skłodowska-Curie Actions860197
TEMPO101039672
European Commission within the fifth framework program37670, QLRT-2001–2455
Alzheimer’s Association-21–831,376-C, -21–831,377-C, ZEN-22–848,604, -21–831,381-C
Vetenskapsrådet101,053,962, 2018–02532, 681,712
Institute of Family Medicine101057529
European Commission101057529, 115736
Alzheimer's Drug Discovery Foundation201,809–2016862
Deutsche Forschungsgemeinschaft2287/6–1, 2654/2–1, LI 2654/4–1
Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden2022-0270
U.S. Department of DefenseW81XWH-12–2-0012, LI- W81XWH2010849
UK Dementia Research InstituteUKDRI-1003
Innovative Medicines Initiative115372
Stiftung Synapsis - Alzheimer Forschung Schweiz AFS2017-PI01
Swedish State Support for Clinical Research-71320
Stichting voor Alzheimer Onderzoek15,005, 11,020, 13,007
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung320030_141179
EU Joint Programme – Neurodegenerative Disease ResearchJPND2021-00694

    Research Areas and Centers

    • Research Area: Medical Genetics

    DFG Research Classification Scheme

    • 2.23-06 Molecular and Cellular Neurology and Neuropathology

    Fingerprint

    Dive into the research topics of 'Multivariate GWAS of Alzheimer’s disease CSF biomarker profiles implies GRIN2D in synaptic functioning'. Together they form a unique fingerprint.

    Cite this